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abstract: We have investigated factors affecting iron distribution in the ﬁrst-trimester gestational sac, by the measurement of trans-
ferrin, non-transferrin-bound iron (NTBI) and pro-hepcidin (Hep) in maternal serum, coelomic ﬂuid (CF) and amniotic ﬂuid (AF) and by
immunostaining for Hep in villous and secondary yolk sac biopsies. These samples were obtained from 15 ﬁrst-trimester pregnancies at
8–11 weeks gestation. Transferrin concentrations were signiﬁcantly lower in fetal (0.56 mg/ml) than maternal serum (1.71 mg/ml), with
very low concentrations in CF and AF (0.09 mg/ml). In contrast, transferrin saturations were signiﬁcantly higher in fetal (77%) than maternal
serum (33%). NTBI was present in fetal serum, CF and AF, presumably as a consequence of low transferrin concentrations in these com-
partments. Pro-Hep was present at lower levels in fetal (140.0+11.1) than maternal serum (206.2+9.2) and at low concentrations in CF
(19.4+3.1) and AF (21.8+5.2). Immunostaining with Hep antibody was found in the syncytiotrophoblast of ﬁrst-trimester placenta as well
as in mesothelial and endodermal layers of the secondary yolk sac at 10 weeks. The presence of Hep in syncytiotrophoblast cells of ﬁrst-
trimester placenta as well as in mesothelial and endodermal layers of the secondary yolk sac suggest a key regulatory role for this protein in
iron transfer to the ﬁrst-trimester fetus. The low transferrin concentrations and the presence of NTBI in CF and AF suggest that transferrin-
independent iron transfer is important in early gestation.
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Introduction
Human iron homeostasis results from tightly coordinated regulation
by the various proteins involved in iron uptake, transport, intracellu-
lar storage and trafﬁcking of iron (Rhoades and Pﬂanzer, 1992). The
human fetus and placenta accumulate around 350 mg of iron during
pregnancy. In adults, two-thirds of the 3000–4000-mg total body
iron content is found in haemoglobin. Most of the remaining iron
is contained in myoglobin and respiratory proteins, stored bound
to ferritin in the liver and spleen, or combined with transferrin.
Transferrin transports the iron absorbed by the intestinal wall or
released from hepatic stores through the plasma for delivery to
the bone marrow and other iron-requiring tissues. In primates,
including humans, the greatest source of iron transferable to the
fetus is that bound to maternal transferrin, and the amount of
iron needed by the fetal tissues is an obligatory requirement that
is met regardless of maternal iron stores. The rate of iron transfer
across the placenta increases with fetal growth and has been
related to the development of fetal haematopoiesis (Rhoades and
Pﬂanzer, 1992; McArdle et al., 2003).
Maternal iron is released into the intervillous space and is rapidly
taken up by transferrin receptors located on the surface of the syncy-
tiotrophoblast (Seligman et al., 1979; Wada et al., 1979). Cellular iron
is probably transported in an uncharacterized low-molecular-weight
form in iron storage granules in the syncytiotrophoblast (Okuyama
et al., 1985; Knisely et al., 1989) or stored bound to ferritin (Brown
et al., 1979) and is released into the fetal circulation to be bound to
transferrin. The anatomy of the ﬁrst-trimester gestational sac in
humans is different to that of other mammalian species and to that
of the second and third trimester (Jauniaux and Gulbis, 2000). In
the ﬁrst-trimester pregnancy, the secondary yolk sac ﬂoats within
the exocoelomic cavity (ECC), is directly connected to the fetal gut
and possesses a rich vascular plexus in contrast with that of early pla-
cental villi. The ECC, which lies between the primitive placenta and
the amniotic cavity, is the largest anatomical space inside the gesta-
tional sac between 5 and 9 weeks of gestation. At the end of the
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progressively obliterated by the growing amniotic cavity and the fetal
circulation shifts from a mainly vitelline to an exclusively villous circula-
tion. The study of the biochemical composition of the coelomic ﬂuid
(CF) in parallel with that of the amniotic ﬂuid (AF), and the
anatomy and biological activities of the surrounding tissue has
enabled us to better understand materno-fetal transfer and to demon-
strate the presence of different metabolic pathways in the ﬁrst trime-
ster of pregnancy compared with later in pregnancy (Jauniaux et al.,
1991, 1996, 2003, 2004, 2007; Gulbis et al., 1998).
As iron is an obligate requirement for feto-placental development
and biological activities, it is important to elucidate the mechanisms
by which fetal iron is acquired and distributed within the ﬁrst-trimester
gestational sac. We have previously found that the concentration of
iron in the CF increases between 7 and 12 weeks of pregnancy, indi-
cating that placental iron transfer increases with advancing gestation
(Gulbis et al., 1994). We have also shown that the ECC contains
very high levels of ferritin when compared with maternal serum and
AF, suggesting that this embryonic cavity is the main reservoir for
iron in early pregnancy. The distribution of iron and other iron-binding
proteins between the maternal and feto-placental compartments in
the ﬁrst trimester is comparable with that found later in gestation,
suggesting that placental transfer of iron, other oligo-elements and
vitamins may occur as early as the formation of tertiary villi (Gulbis
et al., 1994; Jauniaux et al., 2004, 2007).
Ferritin serves to store iron in a non-toxic form and transport it to
various tissues. However, little is known about the release of iron from
ferritin in vivo. Complete proteolytic destruction of the molecule may
be required to secure iron retrieval (Radisky and Kaplan, 1998) This
suggests that ferritin in the ECC may not provide a direct delivery
route for iron to the developing fetus. We have therefore investigated
the presence of other iron-carrying molecules in both the fetal ﬂuids
and blood. Plasma transferrin is the iron transporter in humans and
when transferrin becomes saturated, non-transferrin-bound iron
(NTBI) appears in the plasma and can be taken up into cells (Evans
et al., 2008). Hepcidin (Hep) is a recently described amphipathic
b-sheet hairpin peptide, which is expressed mainly in the liver, as a
longer precursor known as Pro-Hep (Ganz, 2004; Hugman, 2006;
Zhang and Enns, 2009) This iron-regulatory hormone inhibits iron
absorption in the small intestine and is regulated by hypoxia,
anaemia, inﬂammation, dietary iron and iron stores (Ganz and
Nemeth, 2010). It also possesses antimicrobial properties. Although
it has been suggested that, in utero, Hep inhibits iron transport from
maternal blood across the placenta to the fetal circulation, little is
known about the distribution of this molecule inside the ﬁrst-trimester
gestational sac. The aim of this study was therefore to evaluate the dis-
tribution of Hep molecules in early fetal ﬂuids, tissues and blood and
its possible role in the distribution of iron-carrying molecules inside the
ﬁrst-trimester gestational sac.
Materials and Methods
Subjects and samples
CF, AF, fetal blood and maternal blood were obtained at 8–11 weeks
of gestation prior to elective surgical termination of pregnancy under
general anaesthesia. Gestational age was determined from the ﬁrst
day of the last menstrual period and conﬁrmed by ultrasound measure-
ment of the fetal crown-rump length. Written consent was obtained
from each woman after receiving complete information on the pro-
cedure. The study included only uncomplicated pregnancies and was
approved by University College London Hospitals Committee on the
Ethics of Human Research.
CF (n ¼ 10), AF (n ¼ 6) and intra-cardiac fetal blood (n ¼ 5) samples
were obtained by transvaginal puncture under sonographic guidance as
described previously (Jauniaux et al., 1991, 1996, 2007; Gulbis et al.,
1998). AF and fetal blood samples could not be obtained before 8
and 10 weeks of gestation, respectively. The ﬁrst 0.2 ml of CF and
AF was discarded to decrease the risk of contamination by maternal
blood. In all cases, maternal venous blood (n ¼ 15) was obtained
from an antecubital vein during the surgical procedure, and placental
and secondary yolk sac tissues were collected at the end of the pro-
cedure. Samples of maternal and fetal serum and of fetal ﬂuids were
stored at 2808C until assayed.
Three samples of placental villi and decidual tissue and three intact sec-
ondary yolk sacs at 9, 10 and 11 weeks of gestational age were ﬁxed for
immunohistochemistry in 4% paraformaldehyde and embedded in parafﬁn
wax at the end of the surgical procedure.
Bioassays
Samples were assayed for Pro-Hep, transferrin concentration and satur-
ation and NTBI. Due to the lack of availability of commercial methods
for measuring Hep, the concentration of Pro-Hep, the pro-hormone of
Hep was measured in the different series of samples. Pro-Hep ELISA
kits were obtained from DRG International Ltd (Boldon, Tyne and
Wear, UK) and used according to the manufacturer’s instructions. The
detection limit for this assay was ,3.95 ng/ml and the inter-assay coefﬁ-
cient of variations were 9.76, 6.68 and 4.82% for low-, medium- and high-
range samples.
Transferrin concentration was measured using a commercially available
human transferrin ELISA kit (Alpha Diagnostic International, San Antonio,
TX, USA). The minimum detection limit for the assay was 50 ng/ml and
the inter-assay coefﬁcient of variation was 7.0 and 5.5% for low- and high-
range samples, respectively.
The urea gel method of Evans and Williams (1980) was used to
determine transferrin saturation. In brief, polyacrylamide gels are
formed in the presence of 6 M urea which partially denatures the trans-
ferrin molecule to an extent determined by the degree of iron satur-
ation. Apotransferrin, with no bound iron, denatures the most,
followed by the C- and N-terminal monoferric forms with completely
saturated diferric transferrin denaturing the least leaving the diferric
form as a more compact globular species able to migrate more
freely through the gel matrix. Apotransferrin is the least globular and
the four forms are separated when a potential difference is applied
to the gel. The bands were stained using Coomassie Blue and quanti-
tated by scanning the gel into an imaging Programme (Scion Corpor-
ation, Frederick, MD, USA).
NTBI quantiﬁcation was evaluated by the method described by Singh
et al. (1990). In brief, a high concentration of a relatively non-speciﬁc
ligand, nitrilotriacetate (NTA) is used to bind the NTBI, which is then
transferred to a speciﬁc hydroxypyridinone ligand to form a coloured
iron complex that can be quantitated by HPLC. As it is difﬁcult to
exclude contaminant iron from NTA, the assay was run using NTA con-
taining a standard added concentration of iron. Under the conditions
used for the NTBI assay, no iron is removed from transferrin by NTA.
Lower detection limit for the assay was a concentration of 0.5 mM. The
inter-assay coefﬁcient of variation for this assay in our hands was 17.3%
measured over 29 samples and 1 year of sampling.
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Paraformaldehyde-ﬁxed placental villi and secondary yolk sac tissues
embedded in parafﬁn wax were sectioned at 7 mm. After dewaxing and
blocking of endogenous peroxidases by incubation with 3% H2O2 for
30 min, the sections were incubated with non-immune serum for
20 min. Hep antibody (Abcam, UK; used at 1/500) was applied overnight
at 48C, and binding was detected using Vectastain Elite ABC kits (Vector
Laboratories) and SigmaFast DAB (Sigma), according to the manufac-
turers’ instructions. Sections were lightly counterstained with
haematoxylin.
Statistical analysis
A biomedical data processing statistical package (Statgraphics, Manugistics,
Rockville, MD, USA) was used for the analysis. Data were normally distrib-
uted and are presented as the mean and standard error of the means
(SEM). Differences in means of fetal ﬂuids and maternal values were
tested using the analysis of variance and the t-test. Results were con-
sidered statistically signiﬁcant at P , 0.05.
Results
Immunohistochemical staining
Immunolabelling for Hep and cytokeratin 7 was used to identify Hep-
positive cells in the ﬁrst-trimester villi, decidua and secondary yolk sac.
In the placental villi, the antibody labelled the syncytiotrophoblastic
covering of the villi and fetal red blood cells, whereas the cytotropho-
blast, stroma and fetal capillary walls showed no staining (Fig. 1). The
decidual gland cells were negative for Hep.
Hep staining was also apparent in the secondary yolk sac. The anti-
body labelled strongly the cytoplasm of the external mesothelial layer
and to much lesser extent the internal endodermal layer (Fig. 2). The
cytoplasm and nuclei of the mesothelial layer stained uniformly,
whereas the endodermal cytoplasm largely did not stain and none
of the endodermal nuclei reacted positively. The mesenchyme,
blood islands and ducts did not show labelling. Negative control sec-
tions, which were not exposed to primary antibodies, showed no
staining (not shown).
Biochemistry
Table I shows the concentration of transferrin and the proportion of
transferrin saturated by iron (% transferrin sat) measured in the four
ﬂuid compartments. The highest levels of transferrin were found in
maternal serum, where transferrin concentration in all samples was
within normal range (3.0–5.2 mg/ml). Maternal serum mean transfer-
rin concentration was signiﬁcantly higher than fetal serum mean con-
centration (P , 0.05) and ﬂuid mean concentrations (CF and AF,
both P , 0.001). There was no signiﬁcant difference in the mean
transferrin concentration between the CF and the AF. Transferrin
iron saturation also differed across the four ﬂuid compartments. In
maternal serum, the mean saturation was 33.1% (normal range 16–
50%). Transferrin saturation in fetal serum was signiﬁcantly (P ,
0.001) higher with all individual values well above the upper limit of
the range for normal adults. Transferrin saturation was difﬁcult to
measure in CF and AF samples due to the low concentrations of trans-
ferrin present. Feint diferric transferrin bands were visible on the gels
containing the CF samples, whereas no bands corresponding to the
other iron-containing forms were seen. There were no visible bands
on gels containing the AF samples.
Figure 1 Immunostaining with Hep antibody (brown) in the syncy-
tiotrophoblast cells of ﬁrst-trimester placenta at 11 week and in the
fetal and maternal red cells. Nuclei are stained blue (×40).
Figure 2 Immunostaining with Hep antibody (brown) in mesothe-
lial (A and B) and endodermal (A) layers of the secondary yolk sac at
10 week. Nuclei are stained blue (A ×25; B ×75).
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in the maternal sera which had a mean NTBI value of 20.69 mM. An
explanation of the negative value here will be found in the discussion.
NTBI was found in the other compartments with signiﬁcantly (P ,
0.01) higher concentrations in CF than in AF. Fetal serum had the
highest NTBI concentration of all ﬂuids tested.
The Pro-Hep normal range for healthy adult humans determined by
us is 73.4–163.6 ng/ml. Table II presents the mean levels of Pro-Hep
measured in maternal and fetal serum and fetal ﬂuids. Pro-Hep was
not detectable in one sample of CF and in one sample of AF, and
these samples have been excluded from Table II. The mean level of
Pro-Hep was signiﬁcantly lower in CF and fetal serum (P , 0.001
for both) than in MS. Pro-Hep levels in the CF and AF were similar.
Discussion
Iron absorption is tightly regulated as excessive accumulation of iron in
tissues causes widespread organ damage (Halliwell et al., 1992). Free
iron toxicity is linked to the ability of iron to catalyse the generation of
free radicals and related damaging species through the Fenton reac-
tion, leading to oxidative stress (Halliwell and Gutteridge, 2007).
The developing fetus is extremely vulnerable to oxidative stress and
thus iron homeostasis must be more tightly regulated in fetal than in
maternal organs and tissues (Burton et al., 2003). The results of the
present study conﬁrm that the exo-CF is the main reservoir for iron
in early pregnancy and that the secondary yolk sac is the principal
route of entry of iron to the ﬁrst-trimester fetus. Our staining data
also indicate that Hep may play a role in the absorption of iron by
the early fetal adnexae and its systemic distribution before the placen-
tal circulation is fully established.
There is no anatomical barrier between the mesenchyme of the
fetal plate of the placenta and the ECC, and protein electrophoresis
has shown that the CF composition results from an ultraﬁltrate of
maternal serum with the addition of speciﬁc placental and secondary
yolk sac bioproducts (Jauniaux and Gulbis, 2000). The higher concen-
trations of human chorionic gonadotrophin, estradiol, estriol and pro-
gesterone in the CF compared with maternal serum strongly suggest
the presence of a direct pathway between the trophoblast and the
ECC. Morphologically, this may be via the villous stromal channels
and the loose mesenchymal tissue of the chorionic plate. These ﬁnd-
ings indicate that the ECC is a physiological liquid extension of the
early placenta, and an important interface in fetal nutritional pathways.
We have previously found that the CF contains lower iron and trans-
ferrin levels, and a higher level of ferritin compared with maternal
serum, and that iron concentrations in CF increase with advancing ges-
tation (Gulbis et al., 1994). We also found no correlation between CF
and maternal serum for iron and iron-binding protein levels, suggesting
that the placental transfer of iron is tightly regulated and that the fetus
controls its own synthesis of iron-binding proteins. In particular, the
very high CF levels of ferritin found in our previous study indicate
that this molecule is probably of placental and secondary yolk sac
origin.
In humans, the synthesis of transferrin has been demonstrated in
the fetal liver as early as 29 days of gestation (Gitlin and Biasucci,
1969) and a high level of transferrin has been measured in human
fetal plasma as early as 13–14 weeks of gestation (Fryer et al.,
1993). In addition, transferrin molecules may traverse the placenta
in very small amounts and very slowly (Gitlin et al., 1964). In the
present study, we found that transferrin was present at normal con-
centrations and that iron saturation levels were within normal ranges
in the ﬁrst-trimester maternal plasma (Table I). Transferrin concen-
trations were signiﬁcantly lower in fetal serum in comparison with
maternal serum, whereas the iron saturation level was much higher
in fetal serum. Lower transferrin concentrations in fetal serum indicate
that less transferrin iron-binding sites are available to absorb iron and
this can explain the presence of NTBI in fetal serum and ﬂuids.
NTBI is known to be a heterogeneous collection of iron-containing
species, collectively measured by adding a ‘gathering ligand’ such as
NTA (Evans et al., 2008). The NTA–Fe complex is able to transfer
its iron to any unsaturated transferrin present in sera resulting in nega-
tive NTBI concentrations for serum samples with low transferrin sat-
uration such as normal sera and the maternal sera studied here
(Gosriwatana et al., 1999). NTBI is never present at transferrin satur-
ations ,50% and thus a mean transferrin saturation of 33.1% (Table I)
excludes the presence of any NTBI in maternal serum. This situation
can change later in pregnancy in cases where preeclampsia develops
(Casanueva and Viteri, 2003). The very low levels of transferrin
present in CF and AF precludes the absorption of NTBI iron onto
transferrin. Moreover, the presence of feint diferric transferrin bands
strongly suggests that this is the predominant transferrin species
present in CF indicating that the transferrin is highly iron-saturated
and therefore lacking in available binding sites for iron. Therefore,
iron exiting from the trophoblastic cells is likely to accumulate as
NTBI rather than becoming bound to transferrin in fetal ﬂuids.
........................................................................................
Table I Comparison of the mean (SEM) values for
concentrations of iron-containing species in maternal
serum, CF and AF and fetal serum
Compartments Transferrin
(mg/ml)
Transferrin
sat (%)
NTBI (mM)
Maternal serum
(n ¼ 15)
1.77 (0.19) 33.1 (1.6) 20.69 (0.25)
CF (n ¼ 10) 0.09 (0.06) ND 3.06 (0.29)
AF (n ¼ 6) 0.06 (0.03) ND 1.58 (0.29)
Fetal serum
(n ¼ 5)
0.56 (0.05) 77.1 (4.5) 3.67 (0.37)
........................................................................................
Table II Comparison of the mean (SEM) values of
Pro-Hep concentration in maternal plasma, CF and AF
and fetal plasma
Compartments Pro-Hep (ng/ml)
Maternal serum (n ¼ 15) 206.2 (9.2)
CF (n ¼ 9) 19.4 (3.1)
a
AF (n ¼ 5) 21.8 (5.2)
Fetal serum (n ¼ 5) 140.0 (11.1)
b
aSigniﬁcant (P , 0.001) difference between maternal serum and CF.
bSigniﬁcant (P , 0.005) difference between maternal and fetal serum.
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CF and AF.
The results of the present study show for the ﬁrst time that Hep
molecules are present inside the ﬂuids and tissues of the ﬁrst-trimester
human gestational sac. Hep not only controls the rate of iron absorp-
tion but also determines iron mobilization from stores through nega-
tively modulating the function of ferroportin, the only cellular iron
exporter identiﬁed to date (Nemeth et al., 2004). Hep molecules
are pivotal for the developing fetus as high levels of Hep would
inhibit iron release from placental cells. In our ﬂuid studies, we
measured Pro-Hep, an 84 amino acid peptide synthesized by the
liver and from which Hep is excised through proteolytic cleavage
(Hugman, 2006). Like Hep, the synthesis of Pro-Hep is enhanced by
inﬂammation and reduced during hypoxia. In adults, Pro-Hep corre-
lates with indices of iron status and lower levels of Pro-Hep are
found in iron deﬁciency anaemia (Ganz, 2004). We found that the
maternal serum levels of Pro-Hep in the ﬁrst trimester of pregnancy
were within the normal adult range (Table II). Lower levels of maternal
Pro-Hep found later in pregnancy are probably associated with
increased iron demand from the fetus. In the present study, the
lower levels of Pro-Hep in ﬁrst-trimester fetal serum samples
suggest higher levels of iron absorption by the fetus. A recent study
at term has shown that maternal and cord blood Pro-Hep levels cor-
related weakly but signiﬁcantly with placental weight and relative pla-
cental size (Ervasti et al., 2009). Our ﬁnding of lower concentrations
of Pro-Hep in CF and AF than in maternal serum suggests a positive
impact on iron mobilization from cellular stores probably via
ferroportin.
Our immunohistochemistry data indicate positive staining for Hep in
the villous syncytiotrophoblast and the mesothelial layer of the sec-
ondary yolk sac. The endodermal layer of the yolk sac displayed
much less intense staining, whereas the decidual glands did not react
at all with the Hep antibody. Using a similar approach, we have pre-
viously shown a positive immunostaining for a-tocopherol transfer
protein (Jauniaux et al., 2004) and folate receptors-a (Jauniaux
et al., 2007) in the syncytiotrophoblast, uterine glandular epithelial
cells and mesothelial layer of the secondary yolk sac. These data indi-
cate that the maternal uterine glands and the secondary yolk sac play
key roles in supplying these molecules to the developing fetus before
the placental circulation is established. In contrast, the data of the
present study suggest that Hep in fetal ﬂuids is produced by the sec-
ondary yolk sac. The endodermal layer of the secondary yolk sac is
known to synthesize several serum proteins in common with the
fetal liver, such as a-fetoprotein, albumin, pre-albumin and transferrin
(Gitlin and Biasucci, 1969). With rare exceptions, the synthesis of
most of these proteins is conﬁned to the embryonic compartments,
and the contribution of the yolk sac to the maternal protein pool is
limited (Jauniaux and Gulbis, 2000).
The pattern of distribution of iron species in the present study is
consistent with low hepcidin concentrations in developing fetal
tissues and ﬂuids which should favour iron uptake into the fetal com-
partments and iron egress from cells to supply the tissues of the devel-
oping fetus. In the presence of relatively low levels of transferrin, NTBI
would also be expected to appear in the ﬂuids. The question arises as
to the mechanistic role of substances like hepcidin, NTBI and transfer-
rin in supplying and transporting iron to the fetus. Whatever the
mechanism, iron homeostasis has to be carefully controlled inside
the early gestational sac as any imbalance may result in irreversible
damage to fetal tissues (Weinberg, 2010).
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